The billion-dollar expansion of Sanofi’s R&D relationship with antibody platform firm Regeneron Pharmaceuticals, announced in November, effectively turns Regeneron into Sanofi’s external antibody shop through 2017 and gives Paris-based Sanofi a potential bounty of monoclonal antibodies for its pipeline. just as its old-line small molecule products such as the blockbuster blood-thinner clopidogrel (Plavix) face generic competition for the first time.
In the run-up to his first anniversary as CEO of Sanofi, Chris Viehbacher talked about wresting control from scientists who didn't want to look outside for new ideas or products. "I think we have been able to open up the walls of the company," Viehbacher told the Financial Times in November.
There's no greater example of Viehbacher's push than the billion-dollar expansion of Sanofi's R&D relationship with antibody platform firm
Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy
Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.
